A Phase 1, Single Site, Open-label, Uncontrolled Study of FF-21101In / FF-21101Y in Patients with Solid Tumors that Relapsed or Metastasized after Standard Therapy
A Phase 1, Single Site, Open-label, Uncontrolled Study of FF-21101In / FF-21101Y in Patients with Solid Tumors that Relapsed or Metastasized after Standard Therapy
A phase II clinical study of F-1614 in patients with pheochromocytoma (including paraganglioma)
100 Clinical Results associated with PDRadiopharma, Inc.
0 Patents (Medical) associated with PDRadiopharma, Inc.
100 Deals associated with PDRadiopharma, Inc.
100 Translational Medicine associated with PDRadiopharma, Inc.